LLBO Lifeline Biotech Inc (CE)

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced that management will focus efforts to bring its First Warning System� to market in 2009. The First Warning System� is designed to assist in the early detection of breast cancer. Jim Holmes, CEO of Lifeline Biotechnologies, said, �The First Warning System�, with test results from over 700 women, computer software has achieved technology levels in its capabilities of identifying and classifying abnormalities of the breast with sensitivities of 95% to 100% and specificities of 87% to 90%. Last year we filed for a patent covering these technology advances.� Holmes continued to say that, �With these levels of capabilities, the First Warning System� could potentially be commercialized later this year. There is some work ahead of us in order to be in position for market introduction, but it is possible we could, and hopefully, will introduce the system later this year.� Lifeline Biotechnologies, Inc. is focused on market introduction, either directly or through a strategic alliance with a industry partner, the First Warning System�, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry billions of dollars annually, assuming the following are successfully completed: additional clinical trials (if required) and filing and receiving a 510(k) from the FDA, upgrading of hardware and market acceptance of the product. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive, and the terms have been, and may continue to be, dilutive. www.lbti.com Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company�s product and regulatory and shareholder approval for anticipated actions.